Stifel raised the firm’s price target on Neurocrine (NBIX) to $188 from $183 and keeps a Buy rating on the shares. The firm “refreshed diligence” on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $180 from $160 at RBC Capital
- Neurocrine price target raised to $200 from $175 at TD Cowen
- Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
- Neurocrine Extends Eiry W. Roberts’ Employment Term
- Neurocrine’s Promising Prospects: Buy Rating Backed by Osavampator’s Success and Ingrezza’s Revenue Growth